

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

NCT05998408

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Enrollment	145 participants

Key Eligibility Criteria

Inclusion (61)

- ALL COHORTS:
 - Ability of the participant or legally authorized representative (LAR) to understand and be willing to sign a written informed consent document
 - Age 18 or older
 - For females of childbearing potential, stated willingness to use an accepted method of contraception for the duration of the study. Accepted methods of contraception are:
 - Total abstinence
- ... and 56 more (see full listing online)

Exclusion (19)

- An individual who meets any of the following criteria will be excluded from participation in this study:
 - Known diagnosis or high suspicion of constitutional marrow failure syndrome
 - Evidence of a clonal disorder with poor risk cytogenetics per R-IPSS criteria involving chromosome 7 (-7del/-7), chromosome 3 (inv 3/del3/t(3)) or three or more chromosomal abnormalities (complex)
 - MDS with EB-1, EB-2, AML, chronic myelomonocytic leukemia (CMML), MDS/MPN
 - For MDS: Has received hypomethylating agent, chemotherapy, or immunomodulatory therapy within 8 weeks prior to study entry
- ... and 14 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States